Advertisement

---

JAZZ PHARMACEUTICALS PLC

New Research at SLEEP 2013 Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of Misdiagnosis

[2013-06-05] - First U.S. study to highlight severe comorbidities and economic burden associated with narcolepsy
Survey indicates some sleep specialists may not be comfortable diagnosing narcolepsy
Patients' journeys survey shows narcolepsy diagnosis involves multiple physician visits and misdiagnoses


New Research at SLEEP 2013 Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of Misdiagnosis

[2013-06-05] -


Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events

[2013-05-13] -


Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events

[2013-05-13] -


JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS

[2013-05-07] -


JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS

[2013-05-07] - Company Reports Total Revenues of $196 Million Driven by Record Net Sales of Xyrem and Erwinaze
Adjusted EPS of $1.37; GAAP EPS of $0.71
Company Announces up to $200 Million Share Repurchase Program


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers